Poniard Pharmaceuticals CEO Discusses Q3 2010 Results - Earnings Call Transcript

Poniard Pharmaceuticals, Inc. (PARD)

Q3 2010 Earnings Call

November 9, 2010 4:30 PM ET

Executives

Susan Neath – Investor Relations

Ronald Martell – Chief Executive Officer

Mike Jackson – Interim Chief Financial Officer

Dr. Michael Perry – President and Chief Medical Officer

Analysts

Simos Simeonidis – Rodman & Renshaw

Presentation

Operator

Compare to:
Previous Statements by PARD
» Poniard Pharmaceuticals, Inc. Q2 2010 Earnings Call Transcript
» Poniard Pharmaceuticals, Inc. Q1 2010 Earnings Call Transcript
» Poniard Pharmaceuticals, Inc. Q1 2008 Earnings Call Transcript
» Poniard Pharmaceuticals Inc Q4 2007 Earnings Call Transcript

Good day. And welcome to the Poniard Pharmaceuticals [Second] Quarter 2010 Earnings Conference Call. Today’s conference is being recorded. At this time, I would like to turn the conference over to Susan Neath. Please go ahead, Susan.

Susan Neath

Good afternoon. And thank you for joining us. Poniard issued a press release today, which is available on the company’s website at www.poniard.com. Comments made on this call will contain forward-looking statements relating to, among other things, the commercial potential of the company’s picoplatin and product candidates, the company’s corporate strategies and objectives, regulatory and partnering efforts, product development activity, clinical and regulatory goals, financial condition, future expectations and prospects.

Actual results and events may differ materially from those indicated in these forward-looking statements based on a number of important factors, risks and uncertainties, including the company’s anticipated future operating losses, future capital requirements and ability to obtain future funding, the risks that strategic transactions may not be established on a timely basis on terms that are ultimately favorable to the company or at all, the potential safety, efficacy, and commercial viability of picoplatin, the risk that the company’s additional analysis of data from clinical trials of picoplatin may produce negative or inclusive results, or may be inconsistent with previously announced results or previously conducted trials, the company’s ability to retain key personnel, competition from third parties, the company’s ability to preserve and protect intellectual property rights, the company’s dependence on third-party manufacturers, suppliers, and other contractors, changes in technology, government regulation, and general market conditions, the receipt and timing of FDA and other required regulatory approval, and the other risks and uncertainties described in the company’s reports filed with the Securities and Exchange Commission, including the company’s annual report on Form 10-K for the year ended December 31, 2009, and the company’s Form 10-Q for the quarter ended September 30, 2010.

1 2 3 Next › Last »